Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-009694
Filing Date
2025-07-29
Accepted
2025-07-29 07:22:33
Documents
71
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q qure-20250630x10q.htm   iXBRL 10-Q 2467131
2 EX-31.1 qure-20250630xex31d1.htm EX-31.1 14950
3 EX-31.2 qure-20250630xex31d2.htm EX-31.2 14959
4 EX-32.1 qure-20250630xex32d1.htm EX-32.1 14660
  Complete submission text file 0001558370-25-009694.txt   8966228

Data Files

Seq Description Document Type Size
5 EX-101.SCH qure-20250630.xsd EX-101.SCH 51683
6 EX-101.CAL qure-20250630_cal.xml EX-101.CAL 59176
7 EX-101.DEF qure-20250630_def.xml EX-101.DEF 263371
8 EX-101.LAB qure-20250630_lab.xml EX-101.LAB 485315
9 EX-101.PRE qure-20250630_pre.xml EX-101.PRE 373331
74 EXTRACTED XBRL INSTANCE DOCUMENT qure-20250630x10q_htm.xml XML 1517757
Mailing Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP
Business Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP 1-339-970-7000
uniQure N.V. (Filer) CIK: 0001590560 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36294 | Film No.: 251157545
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)